Company Description
Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company...
Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Valuation
Price to Sales Ratio
34.24
Price to Book Ratio
11.40
Enterprise Value to Sales
32.76
Total Debt to Enterprise Value
0.01
Efficiency
Revenue/Employee
375,020.00
Income Per Employee
-903,931.00
Receivables Turnover
0.97
Total Asset Turnover
0.13
Liquidity
Current Ratio
1.46
Quick Ratio
1.46
Cash Ratio
0.93
Profitability
Gross Margin
63.08
Operating Margin
-281.37
Pretax Margin
-236.88
Net Margin
-241.04
Return on Assets
-30.57
Return on Equity
-77.66
Return on Total Capital
-64.88
Return on Invested Capital
-56.75
Capital Structure
Total Debt to Total Equity
6.04
Total Debt to Total Capital
5.69
Total Debt to Total Assets
3.51
Long-Term Debt to Equity
5.30
Long-Term Debt to Total Capital
4.99
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Michael F. Cola | 59 | 2020 | Chief Executive Officer & Director |
Mr. Christopher Sullivan | 35 | 2018 | Vice President-Finance |
Dr. Garry Arthur Neil | 65 | 2020 | Chief Medical Officer |
Dr. Younok Dumortier Shin | - | - | Chief Technology Officer |
Dr. H. Jeffrey Wilkins | 57 | 2020 | Chief Development Officer |
Insider Actions
12/10/2020 |
Garry Arthur Neil Chief Scientific Officer |
3,599 | Acquisition at $2.28 per share. | 8,205 |
12/10/2020 |
James A. Harrell Chief Commercial Officer |
171 | Acquisition at $2.28 per share. | 389 |
12/10/2020 |
Christopher Sullivan Interim CFO |
5,095 | Acquisition at $2.28 per share. | 11,616 |
12/03/2020 |
Armistice Capital LLC Director |
0 | Acquisition at $0 per share. | 0 |
12/03/2020 |
Armistice Capital LLC Director |
20,000 | Acquisition at $2.44 per share. | 48,800 |
11/25/2020 |
Armistice Capital LLC Director |
0 | Acquisition at $0 per share. | 0 |
11/25/2020 |
Armistice Capital LLC Director |
15,000 | Acquisition at $2.39 per share. | 35,850 |
11/24/2020 |
Armistice Capital LLC Director |
0 | Acquisition at $0 per share. | 0 |
11/24/2020 |
Armistice Capital LLC Director |
47,733 | Acquisition at $2.4 per share. | 114,559 |
11/23/2020 |
Armistice Capital LLC Director |
0 | Acquisition at $0 per share. | 0 |
11/23/2020 |
Armistice Capital LLC Director |
37,267 | Acquisition at $2.32 per share. | 86,459 |
09/04/2020 |
Armistice Capital LLC Director |
0 | Acquisition at $0 per share. | 0 |
09/04/2020 |
Armistice Capital LLC Director |
100,000 | Acquisition at $2.2 per share. | 220,000 |
06/10/2020 |
Garry Arthur Neil Chief Scientific Officer |
1,799 | Acquisition at $2.28 per share. | 4,101 |
06/10/2020 |
James A. Harrell Chief Commercial Officer |
6,391 | Acquisition at $2.28 per share. | 14,571 |
06/10/2020 |
Christopher Sullivan Interim CFO |
2,954 | Acquisition at $2.28 per share. | 6,735 |
06/09/2020 |
Armistice Capital LLC Director |
267,806 | Acquisition at $2.52 per share. | 674,871 |
06/09/2020 |
Armistice Capital LLC Director |
0 | Acquisition at $0 per share. | 0 |
06/09/2020 |
Armistice Capital LLC Director |
1,753,680 | Acquisition at $2.5 per share. | 4,384,200 |
06/09/2020 |
Michael F. Cola Chief Executive Officer; Director |
100,000 | Acquisition at $2.5 per share. | 250,000 |
06/09/2020 |
Michael F. Cola Chief Executive Officer; Director |
100,000 | Acquisition at $2.5 per share. | 250,000 |
06/09/2020 |
James A. Harrell Chief Commercial Officer |
10,000 | Acquisition at $2.5 per share. | 25,000 |
06/08/2020 |
Joseph M. Miller Director |
4,472 | Derivative/Non-derivative trans. at $3.22 per share. | 14,399 |
04/09/2020 |
Simon C. Pedder Executive Chairman of the Bd; Director |
20,901 | Derivative/Non-derivative trans. at $2.57 per share. | 53,715 |
MarketWatch News on CERC
-
Big Stock Buys at Winnebago, National CineMedia
- Barron's Online
-
Cerecor started at outperform with $11 stock price target at Oppenheimer
- Tomi Kilgore
-
Starboard Value Urges Zayo Group to Sell Itself
- Barron's Online
-
There’s Value in Damaged Papa John’s Pizza
- Barron's Online
-
Ciao, euro! Global markets gird for the next wave of global populism
- Shawn Langlois
-
Cerecor's stock extends slide, plunges 37% premarket after failed drug trial
- Tomi Kilgore
-
Cerecor says mid-stage trial of treatment for nicotine withdrawal missed its target
- Ciara Linnane
-
Cerecor's stock tumbles 14% premarket after drug trial fails to meet primary endpoint
- Tomi Kilgore
-
Cerecor's stock on track to open at all-time low
- Tomi Kilgore
Other News on CERC
-
Cerecor prices $36.4M stock and warrants offering
- Seeking Alpha
-
Cerecor slumps 12% on stock and pre-funded warrants offering
- Seeking Alpha
-
Cerecor gains on CERC-002 data in mid-stage COVID-19 study
- Seeking Alpha
-
CHU, CHL, FUBO and SKLZ among premarket gainers
- Seeking Alpha
-
CLDR, DOMO, PD and UMC among premarket gainers
- Seeking Alpha
-
Cerecor restarts early-stage CERC-002 study in Crohn’s disease
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
OPK, NBEV among premarket gainers
- Seeking Alpha
-
Enrollment underway in Cerecor CERC-002 study for COVID-19 ARDS
- Seeking Alpha
-
Largest Insider Trades of the Week
- GuruFocus.com
-
Cerecor prices $33M equity offering, shares down 16% premarket
- Seeking Alpha
- Loading more headlines...